Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
Authors' conclusion
In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with a clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.
Study context
- Population
- People with T2D from the SURPASS-1–5 trials; subgroups by baseline urine albumin-to-creatinine ratio (UACR) ≥30 mg/g
- Comparison
- Tirzepatide vs pooled active and placebo comparators
- Primary endpoint
- Change from baseline in UACR
- Follow-up
- Week 40/42
Methodological detailsactive- and placebo-controlled, mixed model for repeated measures, on-treatment data
- Active- and placebo-controlled
- Mixed model for repeated measures
- On-treatment data
Primary result
As reported in the abstract
Adjusted mean % change from baseline in UACR vs all pooled comparators
Each group vs pooled comparatorsAdjusted mean percent change, % (95% CI)
Tirzepatide 5 mg
−19.3(−25.5 to −12.5)
Tirzepatide 10 mg
−22.0(−28.1 to −15.3)
Tirzepatide 15 mg
−26.3(−32.0 to −20.0)
Further findings
UACR by comparator type
- Results similar across pooled placebo, active and insulin comparator studies
UACR, subgroups with baseline UACR ≥30 mg/g
- UACR lowering appeared more pronounced in subgroups with UACR ≥30 mg/g
Mediation analysis
- Approximately one-half of the albuminuria reduction with tirzepatide may be weight loss related
Estimated glomerular filtration rate (eGFR) · week 40/42
- No difference in eGFR between tirzepatide and pooled comparators
Original publication
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials. Diabetes Care. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →